Hisateru Yasui

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu et al. · The Lancet Oncology · 2022 · 768 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

Yasuhide Yamada, Katsuhiko Higuchi, Kazuhiro Nishikawa et al. · Annals of Oncology · 2014 · 533 citations · Full text

Medicine, Oncology, Chemotherapy +10

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Yoshiaki Nakamura, Hiroya Taniguchi, Masafumi Ikeda et al. · Nature Medicine · 2020 · 366 citations

Medicine, Molecular Genetics, Oncology +17

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz et al. · The Lancet Oncology · 2023 · 339 citations

Medicine, Oncology, Pharmacology +16

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

Tsuyoshi Hamaguchi, Ken Kato, Hisateru Yasui et al. · British Journal of Cancer · 2007 · 287 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16